ArticleFrontiers in oncology2021

Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.

Po-Han Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.